Malaria vaccine
- Generic Name
- Malaria vaccine
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
Phase 1
Not yet recruiting
- Conditions
- Malaria,Falciparum
- Interventions
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 56
- Registration Number
- NCT06958198
- Locations
- 🇧🇫
Institut de Recherche en Sciences de la Santé, Sigle,, Boulkiemdé Province, Burkina Faso
Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults
Phase 1
Active, not recruiting
- Conditions
- Prevention of Malaria Transmission and Clinical Malaria
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06507605
- Locations
- 🇲🇱
University of Science, Technique and Technology of Bamako (Usttb), Bamako, Mali
A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )
Phase 2
Not yet recruiting
- Conditions
- Plasmodium Vivax InfectionMalaria Vaccine
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 36
- Registration Number
- NCT05380388
- Locations
- 🇹🇭
Faculty of Tropical Medicine, Bangkok, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath